1
|
Sagna Y, Bagbila WPAH, Sawadogo N, Savadogo PPC, Zoungrana L, Séré L, Yanogo ADR, Saloukou KEM, Zemba D, Zio GU, Zombre YT, Millogo R, Traoré S, Ilboudo A, Bognounou R, Ouedraogo NCJ, Nikiema P, Bengaly S, Gilberte Kyelem C, Guira O, Maniam J, Ogle GD, Ouedraogo MS, Drabo JY. Incidence, prevalence, and mortality of type 1 diabetes in children and youth in Burkina Faso 2013-2022. Diabetes Res Clin Pract 2024; 207:111086. [PMID: 38181985 DOI: 10.1016/j.diabres.2023.111086] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [Key Words] [MESH Headings] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Received: 11/06/2023] [Revised: 12/18/2023] [Accepted: 12/27/2023] [Indexed: 01/07/2024]
Abstract
AIM There are no data on type 1 diabetes (T1D) incidence and prevalence in Burkina Faso. We aimed to determine these in persons aged <25 years (y) since the implementation of Life for a Child (LFAC) program in 2013. PATIENTS AND METHODS Data were collected from the prospective program register. Diagnosis of T1D was clinical, based on presentation, abrupt onset of symptomatic hyperglycemia, need for insulin replacement therapy from diagnosis, and no suggestion of other diabetes types. RESULTS We diagnosed 312 cases of T1D <25y in 2013-2022. Male-to-female ratio was 1:1. T1D incidence <25y per 100,000 population/year increased from 0.08 (CI 95% 0.07-0.60) in 2013 to 0.34 (CI 95% 0.26-0.45) in 2022 (p=0.002). Incidence <15y/y rose from 0.04 (CI 95% 0.01-0.10) to 0.27 (CI 95% 0.18-0.38) per 100,000/year in 2013 and 2022, respectively (p < 0.002). Prevalence per 100,000 population <25y was 0.27 (CI 95% 0.19-0.37) in 2013 and rose to 1.76 (CI 95% 1.546-1.99) in 2022 (p<0.0001). Mortality rate was 20 (CI 95% 13-29.6) per 1,000-person y. CONCLUSIONS There is a low but sharply rising T1D incidence and prevalence rates in children and youth in Burkina Faso since LFAC program implementation. It is very likely this is partly due to improved case detection. Mortality remains substantial.
Collapse
Affiliation(s)
- Yempabou Sagna
- Service de Médecine Interne CHU Sourô Sanou, Bobo-Dioulasso, Burkina Faso; INSSA, Université Nazi BONI, Bobo-Dioulasso, Burkina Faso.
| | - W P Abraham H Bagbila
- Service de Médecine Interne CHU Sourô Sanou, Bobo-Dioulasso, Burkina Faso; INSSA, Université Nazi BONI, Bobo-Dioulasso, Burkina Faso
| | - Nongoba Sawadogo
- Service de Médecine Interne, CHUR de Ouahigouya, Burkina Faso; Faculté de Médecine, Université de Ouahigouya, Ouahigouya, Burkina Faso
| | | | - Lassane Zoungrana
- Service de Médecine Interne, CHU Yalgado Ouedraogo, Ouagadougou, Burkina Faso; UFR/SDS, Université Joseph KI-ZERBO, Ouagadougou, Burkina Faso
| | - Lassina Séré
- Service de Médecine Interne, CHU de Tengandogo, Ouagadougou, Burkina Faso
| | - A Donald R Yanogo
- Service de Médecine Interne, CHU de Tengandogo, Ouagadougou, Burkina Faso
| | | | - Daniel Zemba
- Service de Médecine, CHR de Tenkodogo, Burkina Faso
| | - Gael U Zio
- Service de Médecine, CHR de Tenkodogo, Burkina Faso
| | | | | | - Solo Traoré
- Service de Médecine, CHR de Ziniaré, Médecine, Ziniaré, Burkina Faso
| | | | - Réné Bognounou
- Service de Médecine Interne, CHU Yalgado Ouedraogo, Ouagadougou, Burkina Faso; UFR/SDS, Université Joseph KI-ZERBO, Ouagadougou, Burkina Faso
| | | | - Péré Nikiema
- Service de Médecine, CHR de Koudougou, Médecine, Koudougou, Burkina Faso
| | - Seydou Bengaly
- Service de Médecine Interne, CHU de Tengandogo, Ouagadougou, Burkina Faso
| | - Carole Gilberte Kyelem
- Service de Médecine Interne CHU Sourô Sanou, Bobo-Dioulasso, Burkina Faso; INSSA, Université Nazi BONI, Bobo-Dioulasso, Burkina Faso
| | - Oumar Guira
- Service de Médecine Interne, CHU Yalgado Ouedraogo, Ouagadougou, Burkina Faso; UFR/SDS, Université Joseph KI-ZERBO, Ouagadougou, Burkina Faso
| | - Jayanthi Maniam
- Life for a Child Program, Diabetes NSW & ACT, Sydney, New South Wales, Australia
| | - Graham D Ogle
- Life for a Child Program, Diabetes NSW & ACT, Sydney, New South Wales, Australia
| | - Macaire S Ouedraogo
- Service de Médecine Interne CHU Sourô Sanou, Bobo-Dioulasso, Burkina Faso; INSSA, Université Nazi BONI, Bobo-Dioulasso, Burkina Faso
| | - Joseph Y Drabo
- Service de Médecine Interne, CHU Yalgado Ouedraogo, Ouagadougou, Burkina Faso; UFR/SDS, Université Joseph KI-ZERBO, Ouagadougou, Burkina Faso
| |
Collapse
|
2
|
Walker AF, Graham S, Maple-Brown L, Egede LE, Campbell JA, Walker RJ, Wade AN, Mbanya JC, Long JA, Yajnik C, Thomas N, Ebekozien O, Odugbesan O, DiMeglio LA, Agarwal S. Interventions to address global inequity in diabetes: international progress. Lancet 2023; 402:250-264. [PMID: 37356448 PMCID: PMC10726974 DOI: 10.1016/s0140-6736(23)00914-5] [Citation(s) in RCA: 11] [Impact Index Per Article: 11.0] [Reference Citation Analysis] [Abstract] [MESH Headings] [Grants] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Received: 02/17/2023] [Revised: 04/28/2023] [Accepted: 05/04/2023] [Indexed: 06/27/2023]
Abstract
Diabetes is a serious chronic disease with high associated burden and disproportionate costs to communities based on socioeconomic, gender, racial, and ethnic status. Addressing the complex challenges of global inequity in diabetes will require intentional efforts to focus on broader social contexts and systems that supersede individual-level interventions. We codify and highlight best practice approaches to achieve equity in diabetes care and outcomes on a global scale. We outline action plans to target diabetes equity on the basis of the recommendations established by The Lancet Commission on Diabetes, organising interventions by their effect on changing the ecosystem, building capacity, or improving the clinical practice environment. We present international examples of how to address diabetes inequity in the real world to show that approaches addressing the individual within a larger social context, in addition to addressing structural inequity, hold the greatest promise for creating sustainable and equitable change that curbs the global diabetes crisis.
Collapse
Affiliation(s)
- Ashby F Walker
- Department of Health Services Research, Management and Policy, University of Florida, Gainesville, FL, USA
| | - Sian Graham
- Menzies School of Health Research, Charles Darwin University, Darwin, NT, Australia
| | - Louise Maple-Brown
- Menzies School of Health Research, Charles Darwin University, Darwin, NT, Australia; Department of Endocrinology, Royal Darwin and Palmerston Hospitals, Darwin, NT, Australia
| | - Leonard E Egede
- Department of General Internal Medicine, Center for Advancing Population Science, Medical College of Wisconsin, Milwaukee, WI, USA
| | - Jennifer A Campbell
- Department of General Internal Medicine, Center for Advancing Population Science, Medical College of Wisconsin, Milwaukee, WI, USA
| | - Rebekah J Walker
- Department of General Internal Medicine, Center for Advancing Population Science, Medical College of Wisconsin, Milwaukee, WI, USA
| | - Alisha N Wade
- MRC/Wits Rural Public Health and Health Transitions Research Unit, Wits School of Public Health, University of the Witwatersrand, Johannesburg, South Africa; Division of Endocrinology, Diabetes and Metabolism, Perelman School of Medicine, University of Pennsylvania, Philadelphia, PA, USA
| | - Jean Claude Mbanya
- Division of Endocrinology, Department of Internal Medicine and Specialties, Faculty of Medicine and Biomedical Sciences, University of Yaoundé I, Yaoundé, Cameroon
| | - Judith A Long
- Division of General Internal Medicine, Perelman School of Medicine, University of Pennsylvania, Philadelphia, PA, USA; Corporal Michael J Crescenz VA Medical Center, Philadelphia, PA, USA
| | | | - Nihal Thomas
- Department of Endocrinology, Christian Medical College, Vellore, India
| | | | | | - Linda A DiMeglio
- Department of Pediatrics, Indiana University School of Medicine, Indianapolis, IN, USA
| | - Shivani Agarwal
- Fleischer Institute for Diabetes and Metabolism, Department of Endocrinology, Albert Einstein College of Medicine and Montefiore Medical Center, Bronx, NY, USA; New York Regional Center for Diabetes Translation Research, Albert Einstein College of Medicine, Bronx, NY, USA.
| |
Collapse
|
3
|
Wang XM, Zhong SP, Li GF, Zhuge FY. Diabetes duration or age at onset and mortality in insulin-dependent diabetics: a systematic review and meta-analysis. Diabetol Metab Syndr 2023; 15:147. [PMID: 37393334 DOI: 10.1186/s13098-023-01113-x] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Received: 05/27/2023] [Accepted: 06/15/2023] [Indexed: 07/03/2023] Open
Abstract
BACKGROUND This meta-analysis was conducted given the contradictory findings from studies on the influence of diabetes duration or age at onset on mortality in patients with insulin-dependent diabetes mellitus (IDDM). METHODS Electronic databases (PubMed, Embase, Cochrane, Web of Knowledge, Scopus, and CINHAL) were comprehensively searched to identify relevant studies until October 31, 2022. All of the selected articles contained statistics on hazard ratios, relative risks (RRs), or odds ratios, or data for estimating the association between diabetes duration or age at onset and total mortality in IDDM patients. Regardless the heterogeneity assessed by the I2 statistic, pooled RRs and 95% confidence intervals (CI) for total mortality were acquired via random effect meta-analysis with inverse variance weighting. RESULTS This meta-analysis finally included 19 studies involving 122, 842 individuals. Both age at onset and diabetes duration were positively associated with an increased mortality rate in IDDM patients. Specifically, the pooled RRs for age at onset and diabetes duration were 1.89 (95%CI 1.43-2.50) and 1.89 (95%CI 1.16-3.09) respectively. Subgroup analyses revealed that only prepubertal onset was associated with a greater survival advantage than pubertal or postpubertal onset. CONCLUSIONS The findings of this meta-analysis and systematic review suggest that a later age at onset or longer diabetes duration is associated with increased risk of total mortality in IDDM patients. However, this conclusion shall be interpreted with caution due to the possibility of residual confounding and be confirmed in the future by well-designed studies.
Collapse
Affiliation(s)
- Xing-Mu Wang
- Clinical Laboratory Center, Shaoxing People's Hospital (Shaoxing Hospital, Zhejiang University School of Medicine), Shaoxing, Zhejiang, People's Republic of China
| | - Shu-Ping Zhong
- Department of Hospital Management, Shaoxing People's Hospital (Shaoxing Hospital, Zhejiang University School of Medicine), Shaoxing, Zhejiang, People's Republic of China
| | - Gang-Feng Li
- Clinical Laboratory Center, Shaoxing People's Hospital (Shaoxing Hospital, Zhejiang University School of Medicine), Shaoxing, Zhejiang, People's Republic of China
| | - Fu-Yuan Zhuge
- Department of Endocrine and Metabolism, Shaoxing People's Hospital (Shaoxing Hospital, Zhejiang University School of Medicine), Yuecheng District, No.568, Zhongxing North Road, Shaoxing, Zhejiang, People's Republic of China.
| |
Collapse
|
4
|
Katte JC, McDonald TJ, Sobngwi E, Jones AG. The phenotype of type 1 diabetes in sub-Saharan Africa. Front Public Health 2023; 11:1014626. [PMID: 36778553 PMCID: PMC9912986 DOI: 10.3389/fpubh.2023.1014626] [Citation(s) in RCA: 8] [Impact Index Per Article: 8.0] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 08/08/2022] [Accepted: 01/10/2023] [Indexed: 01/29/2023] Open
Abstract
The phenotype of type 1 diabetes in Africa, especially sub-Saharan Africa, is poorly understood. Most previously conducted studies have suggested that type 1 diabetes may have a different phenotype from the classical form of the disease described in western literature. Making an accurate diagnosis of type 1 diabetes in Africa is challenging, given the predominance of atypical diabetes forms and limited resources. The peak age of onset of type 1 diabetes in sub-Saharan Africa seems to occur after 18-20 years. Multiple studies have reported lower rates of islet autoantibodies ranging from 20 to 60% amongst people with type 1 diabetes in African populations, lower than that reported in other populations. Some studies have reported much higher levels of retained endogenous insulin secretion than in type 1 diabetes elsewhere, with lower rates of type 1 diabetes genetic susceptibility and HLA haplotypes. The HLA DR3 appears to be the most predominant HLA haplotype amongst people with type 1 diabetes in sub-Saharan Africa than the HLA DR4 haplotype. Some type 1 diabetes studies in sub-Saharan Africa have been limited by small sample sizes and diverse methods employed. Robust studies close to diabetes onset are sparse. Large prospective studies with well-standardized methodologies in people at or close to diabetes diagnosis in different population groups will be paramount to provide further insight into the phenotype of type 1 diabetes in sub-Saharan Africa.
Collapse
Affiliation(s)
- Jean Claude Katte
- Institute of Clinical and Biomedical Sciences, University of Exeter Medical School, Exeter, United Kingdom,National Obesity Centre and Endocrinology and Metabolic Diseases Unit, Yaounde Central Hospital, Yaoundé, Cameroon,*Correspondence: Jean Claude Katte ✉
| | - Timothy J. McDonald
- Institute of Clinical and Biomedical Sciences, University of Exeter Medical School, Exeter, United Kingdom,Academic Department of Clinical Biochemistry, Royal Devon and Exeter NHS Foundation Trust, Exeter, United Kingdom
| | - Eugene Sobngwi
- National Obesity Centre and Endocrinology and Metabolic Diseases Unit, Yaounde Central Hospital, Yaoundé, Cameroon,Department of Internal Medicine and Specialities, Faculty of Medicine and Biomedical Sciences, University of Yaoundé 1, Yaoundé, Cameroon
| | - Angus G. Jones
- Institute of Clinical and Biomedical Sciences, University of Exeter Medical School, Exeter, United Kingdom,Macleod Diabetes and Endocrine Centre, Royal Devon and Exeter NHS Foundation Trust, Exeter, United Kingdom
| |
Collapse
|
5
|
Majaliwa ES, Muze KC, Ndayongeje J, Mfinanga SG, Mmbaga BT, Ramaiya K. Correlation of C-Peptide With Complications Observed in Children and Adolescents With Type 1 Diabetes in Tanzania: A Cross-Sectional Survey. Glob Pediatr Health 2023; 10:2333794X231159790. [PMID: 36950323 PMCID: PMC10026112 DOI: 10.1177/2333794x231159790] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 11/08/2022] [Revised: 01/25/2023] [Accepted: 02/08/2023] [Indexed: 03/19/2023] Open
Abstract
Type 1 diabetes mellitus (T1DM) complications corelate with C-peptide levels. However, the C-Peptide role has not been explored in resource limited countries. This study explored the relationship between C-peptide and complications. A cross-sectional study involving participants aged 0 to 25 years with T1DM in Dar es salaam Tanzania, between 2021 and 2022 was done. Diabetes nephropathy and retinopathy were assessed. About 281 (92.4%) participants were screened, 144 (51.2%) were females. Mean age was 19 ± 6 years. Majority 175 (62.3%) had poor glycemic control (HbA1c) > 10%, and low C-Peptide level 201 (71.5%). Retinopathy was 11.7% and risk for nephropathy was 41.3%. About 13.4% and 41.8% with low C peptide had Retinopathy and high-risk nephropathy respectively. Age at diagnosis, poor glycemic control, low c peptide and duration of diabetes were associated with complications. Further prospective studies are needed to capture when complications set in, so to have better strategies to prevent complications.
Collapse
Affiliation(s)
- Edna Siima Majaliwa
- Kilimanjaro Christian Medical
University College, Moshi, United Republic of Tanzania
- Muhimbili National Hospital, Dar es
Salaam, United Republic of Tanzania
- Edna Siima Majaliwa, Kilimanjaro Christian
Medical University College, Box, Moshi 255, United Republic of Tanzania.
| | | | - Joel Ndayongeje
- Global Programmes Tanzania, Dar es
salaam, United Republic of Tanzania
| | | | | | - Kaushik Ramaiya
- Shree Hindu Mandal Hospital, Dar es
salaam, United Republic of Tanzania
| |
Collapse
|